HOWL News and Press, Werewolf Therapeutics Inc. From 11/02/23

2023-11-02 08:37:27 ET Losers: Confluent CFLT -34% after Q3 earning release . Remitly Global RELY -23% after Q3 earning release . Acurx Pharmaceuticals ( ACXP ) -18% announces positive top-line Ibezapolstat phase 2 efficacy results with 96% clinical c...

Interim, first-in-human clinical results from initial monotherapy dose-escalation cohorts in ongoing Phase 1/1b study of WTX-124 including safety and preliminary antitumor activity to be described in poster presentation. Additional posters representing an expansive body of data demonstratin...

2023-10-30 08:34:25 ET Miromatrix Medical ( MIRO ) +225% to buy Miromatrix Medical for $3.25 per share, MIRO jumps 225%. TD Holdings  ( BYU ) +63% . Conduit Pharmaceuticals ( CDT ) +56% . VYNE Therapeutics Inc ( VYNE ) +47% jumps 52% on posit...

2023-10-25 13:11:55 ET Gainers: Abri SPAC I ( ASPA ) +154% . Jaguar Global Growth Corp I ( JGGC ) +88% . Nuvve Holding Corp ( NVVE ) +44% . Data Knights Acquisition Corp ( DKDCA ) +42% . Werewolf Therapeutics ( HOWL ) +28% . ...

Six abstracts, spanning Werewolf’s PREDATOR™ platform and INDUKINE™ pipeline, accepted for poster presentations at SITC annual meeting Company to present interim first-in-human clinical data from initial monotherapy dose-escalation cohorts in ongoing Phase 1/1b study of W...

WATERTOWN, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body&#x...

WATERTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body&#x...

2023-08-24 13:04:58 ET A Massachusetts-based biotech company is turning heads on Thursday after it was announced that Webush Securities initiated coverage on the stock with an outperform rating and a $9.00 price target. Seeing that the stock closed at just $2.58 yesterday, naturally traders...

2023-08-24 12:05:42 ET More on Werewolf Werewolf assumed Buy at Jefferies ahead of data for key cancer drug Werewolf Therapeutics jumps ~10% after RA Capital ups stake, says may engage in talks Werewolf Therapeutics stock rises as HC Wainwright places Buy rating over...

2023-08-10 10:32:34 ET Werewolf Therapeutics press release ( NASDAQ: HOWL ): Q2 GAAP EPS of -$0.14 beats by $0.27 . Revenue of $8.08M (+94.7% Y/Y) beats by $4.93M . For further details see: Werewolf Therapeutics GAAP EPS of -$0.14 beats by $0.27, revenue ...